California-based Gossamer Bio announced Monday that it is discontinuing the development of its lymphoma candidate GB5121 following two patient deaths in the Phase Ib/II STAR-CNS study.
https://www.pharmalive.com/wp-content/uploads/2023/04/BioSpacephysician4-4-2023.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-04-04 12:20:042023-04-04 12:20:04Gossamer cuts lymphoma drug after two fatalities
